Terry McGuire brings more than 25 years of successful early stage investing experience in medical and information technology companies to the LS Polaris Innovation Fund team.
Prior to starting Polaris in 1996, McGuire spent 7 years at Burr, Egan, Deleage & Co. investing in early stage medical and information technology companies. McGuire began his career in venture capital at Golder, Thoma and Cressey in Chicago.
As a venture capitalist, McGuire has invested in more than 50 companies. He also co-founded three companies: Inspire Pharmaceuticals (public and sold to Merck), AIR (sold to Alkermes) and MicroCHIPS (private). Companies McGuire has supported have touched more than 60 million patients and directly saved over 400,000 lives. These companies have raised over $6 billion in equity and corporate capital. As a group, they have achieved a combined peak enterprise value of over $50 billion.
In 2015, McGuire was listed as one of Scientific American’s Worldview 100, visionaries who continue to reshape biotechnology and the world. In 2014, McGuire was chosen to receive the Irish America Healthcare & Life Sciences 50 Award. In 2013, McGuire was listed as one of Forbes’ Top Life Sciences Investors, and he received The Boston Irish Business Award. In 2011, McGuire was listed in Forbes’ Midas 100 List of Top Tech Investors. He is also a recipient of the Massachusetts Society for Medical Research Award, and the Albert Einstein Award for Outstanding Achievement in the Life Sciences, awarded by Harvard and the City of Jerusalem. He was awarded an honorary doctorate degrees from Ohio Wesleyan University and Canisius College for his work in translational science.
McGuire is emeritus Chairman of the National Venture Capital Association (NVCA), which represents ninety percent of the venture capitalists in the United States. During his tenure as NVCA Chairman, McGuire testified before Congress for Dodd-Frank Wall Street Reform and Consumer Protection Act. He is also Chairman of the Global Venture Capital Congress.
McGuire chairs the board of the Thayer School of Engineering, Dartmouth College. He sits on the boards of MIT’s The David H. Koch Institute for Integrative Cancer Research, The Arthur Rock Center for Entrepreneurship at Harvard Business School (HBS), and The Healthcare Initiative Advisory Board (HBS). McGuire also serves on the Board of Directors of Cyclerion Therapeutics.
McGuire holds an MBA from Harvard Business School, an MS in engineering from The Thayer School at Dartmouth College, and a BS in physics and economics from Hobart College.